A number of research firms have changed their ratings and price targets for Core Laboratories N.V. (NYSE: CLB):

  • 9/12/2017 – Core Laboratories N.V. was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Core Laboratories boasts of a unique business model, disciplined financial management and technological expertise. We also like CLB's leadership position in the reservoir optimization niche, along with its global footprint and deep portfolio of proprietary products and services. CLB’s low asset intensive operations and limited capex needs allow it to generate substantial free cash flows and operate profitably even in this low commodity price environment. However, we are concerned of the company’s high leverage and paucity of deepwater drilling orders which might hamper the specialized service provider’s near-term results. Therefore until the commodity price environment improves, we take a cautious stance on the prospects of the stock.”
  • 9/7/2017 – Core Laboratories N.V. had its price target lowered by analysts at Royal Bank Of Canada from $115.00 to $112.00. They now have an “outperform” rating on the stock.
  • 9/1/2017 – Core Laboratories N.V. had its “hold” rating reaffirmed by analysts at Cowen and Company. They now have a $100.00 price target on the stock.
  • 9/1/2017 – Core Laboratories N.V. was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 9/1/2017 – Core Laboratories N.V. had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $115.00 price target on the stock.
  • 8/24/2017 – Core Laboratories N.V. was upgraded by analysts at Credit Suisse Group from a “neutral” rating to an “outperform” rating. They now have a $110.00 price target on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 8/14/2017 – Core Laboratories N.V. was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 8/7/2017 – Core Laboratories N.V. had its price target lowered by analysts at Morgan Stanley from $130.00 to $125.00. They now have an “overweight” rating on the stock.
  • 8/4/2017 – Core Laboratories N.V. was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 7/31/2017 – Core Laboratories N.V. was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/26/2017 – Core Laboratories N.V. was given a new $97.00 price target on by analysts at Piper Jaffray Companies. They now have a “hold” rating on the stock.
  • 7/26/2017 – Core Laboratories N.V. had its “neutral” rating reaffirmed by analysts at UBS AG. They now have a $110.00 price target on the stock, down previously from $125.00.
  • 7/26/2017 – Core Laboratories N.V. had its price target lowered by analysts at Citigroup Inc. from $102.00 to $100.00. They now have a “neutral” rating on the stock.
  • 7/17/2017 – Core Laboratories N.V. was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong sell” rating. According to Zacks, “Core Laboratories is anticipated to face near-term headwinds. Weak commodity prices have prompted upstream firms to lower capital spending, which has resulted in lesser work for the likes of Core Laboratories. Since crude prices are expected to remain low well into 2017, cash flows could see a significant decline in the coming months. The paucity of deepwater drilling orders and lower levels of new wells, which will hamper the specialized service provider’s near-term results, are other negatives in the CLB story. Therefore, ahead of its second-quarter results, we see the company as a risky bet that is best avoided at the moment.”

Shares of Core Laboratories N.V. (CLB) traded up 1.43% during mid-day trading on Thursday, hitting $96.03. The stock had a trading volume of 539,146 shares. The stock’s 50-day moving average is $93.43 and its 200 day moving average is $104.58. The firm has a market cap of $4.24 billion, a PE ratio of 58.91 and a beta of 1.60. Core Laboratories N.V. has a 12 month low of $86.55 and a 12 month high of $125.83.

Core Laboratories N.V. (NYSE:CLB) last issued its earnings results on Monday, July 24th. The oil and gas company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.51 by $0.01. The firm had revenue of $163.90 million during the quarter, compared to the consensus estimate of $168.23 million. Core Laboratories N.V. had a net margin of 11.80% and a return on equity of 49.29%. The company’s revenue was up 10.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.35 earnings per share. Equities research analysts predict that Core Laboratories N.V. will post $2.00 earnings per share for the current fiscal year.

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Receive News & Ratings for Core Laboratories NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories NV and related companies with MarketBeat.com's FREE daily email newsletter.